Article
Salarius hits pause on enrollment of lead sarcoma asset trial after patient death
Rating:
0.0
Views:
63
Likes:
1
Library:
1
Salarius Pharmaceuticals has paused enrollment on a phase 1/2 trial of its lead candidate following the death of one patient.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value